Compare Stocks: TBPH, TARS, ARQT, and MOR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$26.58 +8.5%	$25.33	$19.30 ▼ $31.77	$3.08B	1.57	3.51 million shs	1.73 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
TARS Tarsus Pharmaceuticals	$73.16 +1.3%	$74.50	$53.89 ▼ $91.53	$3.17B	0.44	747,312 shs	481,752 shs
TBPH Theravance Biopharma	$17.03	$17.01	$13.08 ▼ $21.03	$884.18M	0.25	680,323 shs	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	+8.53%	+5.64%	+11.49%	-4.18%	+25.14%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
TARS Tarsus Pharmaceuticals	+1.30%	+0.22%	-11.61%	+25.83%	+4.89%
TBPH Theravance Biopharma	0.00%	0.00%	-0.18%	+0.59%	+17.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$26.58 +8.5%	$25.33	$19.30 ▼ $31.77	$3.08B	1.57	3.51 million shs	1.73 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
TARS Tarsus Pharmaceuticals	$73.16 +1.3%	$74.50	$53.89 ▼ $91.53	$3.17B	0.44	747,312 shs	481,752 shs
TBPH Theravance Biopharma	$17.03	$17.01	$13.08 ▼ $21.03	$884.18M	0.25	680,323 shs	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	+8.53%	+5.64%	+11.49%	-4.18%	+25.14%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
TARS Tarsus Pharmaceuticals	+1.30%	+0.22%	-11.61%	+25.83%	+4.89%
TBPH Theravance Biopharma	0.00%	0.00%	-0.18%	+0.59%	+17.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.70	Moderate Buy	$36.00	35.44% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	2.70	Moderate Buy	$100.86	37.86% Upside
TBPH Theravance Biopharma	2.00	Hold	$19.40	13.92% Upside

Current Analyst Ratings Breakdown

Latest TBPH, TARS, ARQT, and MOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	ARQT Arcutis Biotherapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$39.00
10/6/2026	TARS Tarsus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/24/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
9/24/2026	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$116.00
9/24/2026	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$116.00
9/24/2026	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$110.00
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$110.00
9/8/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/8/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$88.00 ➝ $105.00
9/7/2026	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$376.07M	8.88	N/A	N/A	$1.55 per share	17.15
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
TARS Tarsus Pharmaceuticals	$451.36M	7.11	N/A	N/A	$8.09 per share	9.04
TBPH Theravance Biopharma	$104.31M	8.48	N/A	N/A	$5.86 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	126.58	23.32	N/A	6.15%	15.05%	6.51%	10/27/2026 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	121.93	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)
TBPH Theravance Biopharma	$105.89M	$1.01	16.86	21.02	N/A	51.58%	-0.77%	-0.46%	11/10/2026 (Estimated)

Latest TBPH, TARS, ARQT, and MOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	TARS Tarsus Pharmaceuticals	-$1.49	N/A	N/A	N/A	$182.74 million	N/A
10/27/2026	Q3 2026	ARQT Arcutis Biotherapeutics	$0.1843	N/A	N/A	N/A	$141.94 million	N/A
8/10/2026	Q2 2026	TBPH Theravance Biopharma	$0.0725	-$0.11	-$0.1825	-$0.11	$22.49 million	$20.73 million
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.46	2.92	2.67
MOR MorphoSys	4.98	1.38	1.38
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17
TBPH Theravance Biopharma	N/A	13.54	13.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
MOR MorphoSys	18.38%
TARS Tarsus Pharmaceuticals	90.01%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
MOR MorphoSys	0.05%
TARS Tarsus Pharmaceuticals	9.64%
TBPH Theravance Biopharma	7.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	354	125.69 million	113.88 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
TARS Tarsus Pharmaceuticals	370	43.88 million	39.65 million	Optionable
TBPH Theravance Biopharma	110	51.92 million	47.95 million	Optionable

TBPH, TARS, ARQT, and MOR Headlines

Recent News About These Companies

Head to Head Contrast: Lifecore Biomedical (NASDAQ:LFCR) & Theravance Biopharma (NASDAQ:TBPH)

October 1, 2026 | americanbankingnews.com

Zymeworks completes $17 per share Theravance deal

September 28, 2026 | grafa.comG

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell Small Cap Completeness Index

September 24, 2026 | marketscreener.comM

Theravance Biopharma, Inc. annonce des changements au sein de son conseil d’administration, effectifs au 23 septembre 2026

September 24, 2026 | zonebourse.comZ

Theravance Biopharma, Inc. annonce la démission de Rick E Winningham de son poste de directeur général, effective le 23 septembre 2026

September 24, 2026 | zonebourse.comZ

Theravance Biopharma (NASDAQ:TBPH) Receives Neutral Rating from BTIG Research

September 24, 2026 | marketbeat.com

Zymeworks Inc. (NasdaqGS:ZYME) hat Theravance Biopharma, Inc. (NasdaqGM:TBPH) übernommen.

September 24, 2026 | de.marketscreener.comD

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P TMI Index

September 23, 2026 | marketscreener.comM

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Global BMI Index

September 22, 2026 | marketscreener.comM

Theravance Biopharma (NASDAQ:TBPH) Sees Unusually-High Trading Volume - Still a Buy?

September 22, 2026 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Recommendation of "Hold" by Analysts

September 22, 2026 | marketbeat.com

Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow

September 18, 2026 | seekingalpha.com

Theravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 Shares

September 18, 2026 | insidertrades.com

Insider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 Shares

September 17, 2026 | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.07 Million in Theravance Biopharma, Inc. $TBPH

September 14, 2026 | marketbeat.com

Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?

September 9, 2026 | zacks.com

Theravance Biopharma Inc

August 20, 2026 | money.usnews.com

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

August 15, 2026 | businesswire.com

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

August 11, 2026 | zacks.com

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 | prnewswire.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 6, 2026 | financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TBPH, TARS, ARQT, and MOR Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$26.58 +2.09 (+8.53%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$26.56 -0.02 (-0.08%)

As of 10/9/2026 07:47 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 10/8/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Tarsus Pharmaceuticals NASDAQ:TARS

$73.16 +0.94 (+1.30%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$74.32 +1.16 (+1.58%)

As of 10/9/2026 07:30 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Theravance Biopharma NASDAQ:TBPH

$17.03 0.00 (0.00%)

As of 10/8/2026

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TBPH, TARS, ARQT, and MOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TBPH, TARS, ARQT, and MOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TBPH, TARS, ARQT, and MOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TBPH, TARS, ARQT, and MOR Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

MorphoSys NASDAQ:MOR

Tarsus Pharmaceuticals NASDAQ:TARS

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TBPH, TARS, ARQT, and MOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TBPH, TARS, ARQT, and MOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TBPH, TARS, ARQT, and MOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TBPH, TARS, ARQT, and MOR Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

MorphoSys NASDAQ:MOR

Tarsus Pharmaceuticals NASDAQ:TARS

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools